Statements (48)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:healthcare_organization
|
| gptkbp:activities |
reduces inflammation
modulates gene expression inhibits keratinocyte proliferation |
| gptkbp:appointed_by |
gptkb:tablet
gptkb:skincare_product |
| gptkbp:approves |
gptkb:1997
gptkb:FDA |
| gptkbp:clinical_trial |
safety profile assessment
long-term use effects efficacy in acne treatment efficacy in psoriasis treatment |
| gptkbp:contraindication |
pregnancy
breastfeeding sensitivity to retinoids |
| gptkbp:developed_by |
gptkb:Galderma
|
| gptkbp:formulation |
0.05% strength
0.1% strength |
| https://www.w3.org/2000/01/rdf-schema#label |
tazarotene
|
| gptkbp:ingredients |
C21 H20 O2
|
| gptkbp:interacts_with |
may increase sensitivity to sunlight
may interact with topical corticosteroids should not be used with other retinoids |
| gptkbp:is_available_on |
prescription medication
|
| gptkbp:is_used_for |
psoriasis
acne photoaging |
| gptkbp:marketed_as |
Tazorac
|
| gptkbp:pharmacokinetics |
excreted in urine
metabolized in the liver improves skin texture topical absorption affects skin cell turnover increases collagen production |
| gptkbp:related_to |
retinoids
vitamin A derivatives |
| gptkbp:side_effect |
skin irritation
dry skin redness burning sensation |
| gptkbp:storage |
store at room temperature
keep away from moisture do not freeze |
| gptkbp:traded_on |
Avage
Tazorac |
| gptkbp:type_of |
118585-55-5
|
| gptkbp:bfsParent |
gptkb:Retin-A
|
| gptkbp:bfsLayer |
7
|